display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
metastatic/advanced RCC (mRCC) - 1st line (L1)
metastatic/advanced RCC (mRCC) - 1st line (L1)
VEGF(R) inhibitor
lenvatinib
lenvatinib in association KEYNOTE-581/CLEAR ...

Study type: